HealthTech Innovation Days (HTID®), Paris, France & Virtual Conference

Chardan 4th Annual Genetic Medicines Conference – Virtual

GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

H.C. Wainwright 22nd Annual Global Investment Conference – Virtual Conference

GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)